NRG1 fusions in breast cancer.

ABSTRACT:

Background

NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric receptor tyrosine kinase, and the gene fusions are thought to lead to autocrine stimulation of the receptor. The NRG1 fusion expressed in the breast cancer cell line MDA-MB-175 serves as a model example of such fusions, showing the proposed autocrine loop and exceptional drug sensitivity. However, its structure has not been properly characterised, its oncogenic activity has not been fully explained, and there is limited data on such fusions in breast cancer.

Methods

We analysed genomic rearrangements and transcripts of NRG1 in MDA-MB-175 and a panel of 571

SUBMITTER: Howarth KD 

PROVIDER: S-EPMC7788813 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature